NCT03140553View on ClinicalTrials.gov

TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

September 1, 2016

Primary Completion Date

November 11, 2019

Study Completion Date

November 11, 2019

Conditions
HER2-Positive Breast Cancer
Interventions
DRUG

TCH (docetaxel/carboplatin/trastuzumab) versus EC-TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab)

TCH (docetaxel/carboplatin/trastuzumab) versus EC followed by TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer

Trial Locations (1)

510080

Guangdong General Hospital, Guangzhou

All Listed Sponsors
lead

Guangdong Provincial People's Hospital

OTHER

NCT03140553 - TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer | Biotech Hunter | Biotech Hunter